SecBot SecBot
SECBOTREPLAY Home › Report › SABS

SABS · SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs…

SAB Biotherapeutics, Inc. · PRESS-RELEASE filed May 12, 2026 at 07:30 ET

At the news

BEARISHIMPACT 7/10

PRESS-RELEASE filed May 12, 2026 at 07:30 ET

SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs consensus of -$0.21, with net loss widening to $18.9M from $5.2M a year ago. The company highlighted continued SAFEGUARD trial enrollment progress, FDA acceptance of C-peptide as a surrogate endpoint for accelerated approval, and a strong $217.6M cash position providing runway through 2028.

  • Q1 2026 EPS of -$0.35 missed consensus of -$0.21 by 68.3%
  • Net loss widened to $18.9M from $5.2M in Q1 2025
  • R&D expenses increased to $13.4M from $7.7M YoY
  • Cash position of $217.6M at March 31, 2026, providing runway through 2028

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access